A BioCentury analysis of ESMO first-in-human abstracts finds antibody-drug conjugates outnumbering every other modality, even as payload innovation lags behind target innovation. On the latest BioCentury This Week podcast, BioCentury's analysts discuss why new targets alone may not be enough to overcome resistance.
Turning to policy, the analysts examine Representative Jake Auchincloss’ Faster Clinical Trials Act, which would embed trials in routine care and expand the NIH's All of Us biobank. They also discuss how U.S. investors are reacting to Treasury's proposed COINS Act rule, including a workaround that pays Chinese licensors on exit instead of with equity, and former FDA Commissioner Janet Woodcock's proposals to make individualized rare disease therapies commercially viable.
View full story: https://www.biocentury.com/article/661405
#ADCs #ClinicalTrials #BiotechPolicy #ChinaBiotech #RareDisease
0:00 Introduction
1:34 ESMO First-in-Human Analysis
10:26 Faster Clinical Trials Act
19:27 COINS Act and NewCos
28:19 Woodcock's Rare Disease Proposals
31:53 Biotech IPO Debuts
To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected].
Altri episodi di "BioCentury This Week"
Non perdere nemmeno un episodio di “BioCentury This Week”. Iscriviti all'app gratuita GetPodcast.
